Overview
OraSure Q3 revenue declines 32% yr/yr, missing analyst expectations
Adjusted operating income for Q3 beats analyst estimates
Company repurchased 1.5 mln shares for $5 mln in Q3
Outlook
Company guides Q4 2025 revenues between $25 mln and $28 mln
OraSure plans new product launches in rapid diagnostics and sample management solutions in 2026
Company sees strong balance sheet aiding navigation of short-term turbulence
Result Drivers
FUNDING UNCERTAINTY - Co says some customers face uncertainty in funding for public health programs, impacting core business revenues
PRODUCT LAUNCHES - Co expects growth from new product launches in rapid diagnostics and sample management solutions next year
DECLINE IN HIV TEST REVENUE - Diagnostics revenues decreased 34% yr/yr due to lower revenue from HIV tests
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $27.10 mln | $29.13 mln (3 Analysts) |
Q3 Gross Margin | 43.50% | ||
Q3 Adjusted Operating Income | Beat | -$12.70 mln | -$18.05 mln (2 Analysts) |
Q3 Operating Income | -$16.10 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for OraSure Technologies Inc is $4.75, about 45.9% above its November 4 closing price of $2.57
Press Release: ID:nGNX5s5HCg
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments